SCHEMBL17009264

SCHEMBL17009264

CC1CCCNC1CN1C(=O)c2ccccc2C1=O

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
KEAP1 Q14145 1/20 0.41
NFE2L2 Q16236 1/20 0.41
ACHE P22303 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.38
ALDH1A1 P00352 4/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
CYP1B1 Q16678 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16277278 1.00 CYP2C9 (0.47) CYP2C9CYP1A2CYP2C19KEAP1NFE2L2
SCHEMBL16277451 1.00 CYP2C9 (0.47) CYP2C9CYP1A2CYP2C19KEAP1NFE2L2
SCHEMBL14563296 0.79 CYP1A2 (0.51) CYP2C9CYP1A2CYP2C19KEAP1NFE2L2
SCHEMBL15672061 0.79 CYP1A2 (0.51) CYP2C9CYP1A2CYP2C19KEAP1NFE2L2
Hydrochloric Acid SCHEMBL5426189 0.78 CYP1A2 (0.50) CYP2C9CYP1A2CYP2C19KEAP1NFE2L2
SCHEMBL14921361 0.75 CYP1A2 (0.50) CYP2C9CYP1A2CYP2C19KEAP1NFE2L2
SCHEMBL25579206 0.72 ACHE (0.44) CYP2C9CYP1A2CYP2C19ACHEHSD17B10
SCHEMBL25266833 0.71 KEAP1 (0.44) CYP2C9CYP1A2CYP2C19KEAP1ACHE
SCHEMBL25202810 0.71 KEAP1 (0.44) CYP2C9CYP1A2CYP2C19KEAP1ACHE
SCHEMBL8268236 0.71 CYP1A2 (0.49) CYP2C9CYP1A2CYP2C19CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015123355-A1 SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS EOLAS THERAPEUTICS, INC. (US) 2015-08-20 WO disclosed